PDUFA Date
ARVN: PDUFA Date: vepdegestrant
June 5, 2026 · vepdegestrant. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 5, 2026
- Company
- ARVINAS, INC. (ARVN)
- Drug
- vepdegestrant
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
PDUFA Date
PDUFA Date: vepdegestrant
- Company
- ARVINAS, INC. (ARVN)
- Drug
- vepdegestrant
- Indication
- 1 INDICATIONS AND USAGE VEPPANU is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1) -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. VEPPANU is a heterobifunctional protein degrader indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal gr